Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$98.82 USD

98.82
666,765

+1.62 (1.67%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 250)

Industry: Medical Services

Zacks News

Avantor's (AVTR) New Offerings to Aid Cell and Gene Therapy Suite

Avantor's (AVTR) latest offerings are likely to provide its customers with products, materials and services that would aid in accelerating therapeutics.

Masimo's (MASI) Latest Tie-Up to Boost Patient Monitoring

Masimo's (MASI) latest joint effort is likely to enable real-time continuous monitoring with a tailored view of the patient's vitals while keeping them mobile during critical recovery periods.

Catalent (CTLT) to Report Q1 Earnings: What's in the Cards?

Catalent's (CTLT) fiscal Q1 results are likely to be affected by soft performance by the Biologics segment.

Veradigm's (MDRX) New Offering to Enhance Patient Engagement

Veradigm's (MDRX) latest solution is likely to offer its clients the right payment option to each individual patient through the right communication channel.

Cardinal Health (CAH) Launches Surgical Gown for Safe Surgery

Cardinal Health's (CAH) SmartGown EDGE Breathable Surgical Gown will enable clinical teams to focus on delivering safe patient care by reducing instrument handoffs and contamination.

Insulet (PODD) Banks on Omnipod for Consistent Market Share Gain

Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.

Why HealthEquity (HQY) Could Beat Earnings Estimates Again

HealthEquity (HQY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?

Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited fiscal fourth-quarter sales.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Reasons to Add Patterson Companies (PDCO) in Your Portfolio Now

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

CareDx (CDNA) Surges 16.6%: Is This an Indication of Further Gains?

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Down -8.48% in 4 Weeks, Here's Why You Should You Buy the Dip in HealthEquity (HQY)

HealthEquity (HQY) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

ELV vs. HQY: Which Stock Is the Better Value Option?

ELV vs. HQY: Which Stock Is the Better Value Option?

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Labcorp (LH) Q3 Earnings and Revenues Beat, Margins Fall

Labcorp (LH) delivers a strong performance in the third quarter of 2023 across the Diagnostics Laboratories and Biopharma Laboratory Services businesses.

Align Technology (ALGN) Q3 Earnings Miss, Operating Margin Up

Align Technology's (ALGN) Q3 fiscal 2023 performance reflects revenue growth across all regions.

Here's Why You Should Invest in Haemonetics (HAE) Right Now

Investors are optimistic about Haemonetics (HAE) on robust volume growth in the Plasma business and upbeat guidance.

Revvity's (RVTY) New Tie-Up to Boost NGS Research Workflow

Revvity's (RVTY) latest partnership is likely to address the workflow-related challenges faced by labs and democratize genomic sequencing.

Baxter's (BAX) New Launch to Enable Earlier Treatment of Eye

Baxter's (BAX) latest offering is likely to enable a more digitally-connected primary care examination and support faster diagnosis for earlier treatment of eye conditions.

Abbott (ABT) Q3 Earnings and Revenues Surpass, Margins Dip

Abbott (ABT) reports solid underlying base business performance in the third quarter of 2023.

Here's Why You Should Add DaVita (DVA) Stock to Your Portfolio

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

Here's Why You Should Add Cencora (COR) to Your Portfolio Now

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

PacBio's (PACB) New Offering to Boost WGS Data Analysis

PacBio's (PACB) latest software pipeline is likely to provide standardization to HiFi WGS analysis.

3 Reasons to Add Integer Holdings (ITGR) Stock to Your Portfolio

Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.

ELV vs. HQY: Which Stock Should Value Investors Buy Now?

ELV vs. HQY: Which Stock Is the Better Value Option?